Company Immunic, Inc.

Equities

IMUX

US4525EP1011

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
1.22 ^USD	-3.17%		+3.39%	-18.67%

04-09	Transcript : Immunic, Inc. - Special Call
03-21	Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	MT

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Companyâs s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Number of employees: 77

Managers	Title	Age	Since
Daniel Vitt CEO	Chief Executive Officer	55	31/12/16
Glenn Whaley DFI	Director of Finance/CFO	56	30/11/19
Hella Kohlhof CTO	Chief Tech/Sci/R&D Officer	51	31/12/16
Andreas Muehler CTO	Chief Tech/Sci/R&D Officer	60	31/07/16
Jessica Breu IRC	Investor Relations Contact	-	-
Patrick Walsh PRN	Corporate Officer/Principal	41	13/10/21
Inderpal Singh LAW	General Counsel	58	31/05/21

Members of the board	Title	Age	Since
Barclay Phillips BRD	Director/Board Member	61	18/11/19
Tamar Howson BRD	Director/Board Member	75	10/10/19
Jörg Neermann BRD	Director/Board Member	57	31/03/19
Daniel Vitt CEO	Chief Executive Officer	55	31/12/16
Duane Nash CHM	Chairman	53	31/12/18
Richard Rudick BRD	Director/Board Member	73	25/04/23
Monika Tornsen BRD	Director/Board Member	45	04/07/22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	90,079,016	83,120,924 ( 92.28 %)	0	92.28 %

Name	Equities	%	Valuation
Adage Capital Management LP 6.221 %	5,594,406	6.221 %	7 M $
RTW Investments LP 4.821 %	4,335,255	4.821 %	6 M $
LSP Management Group BV 2.405 %	2,162,782	2.405 %	3 M $
Roland Oetker 2.196 %	1,974,571	2.196 %	3 M $
Gratus Capital LLC 2.159 %	1,941,454	2.159 %	3 M $
Omega Fund Management LLC 1.988 %	1,788,160	1.988 %	2 M $
Vanguard Global Advisers LLC 1.880 %	1,691,000	1.880 %	2 M $
UBS O'Connor LLC 0.6675 %	600,234	0.6675 %	792 309 $
Acadian Asset Management LLC 0.6219 %	559,305	0.6219 %	738 283 $
Logos Global Management LP 0.4684 %	421,184	0.4684 %	555 963 $

Immunic, Inc.

1200 Avenue of the Americas Suite 200

10036, New York

http://www.immunic-therapeutics.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.22 USD

Average target price

11.5 USD

Spread / Average Target

+842.62%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNIC, INC.	-18.67%	110M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs